Introduction
Recombinant proteins are proteins that are produced through genetic engineering techniques, where the DNA sequence encoding the desired protein is inserted into a host organism for expression. One such recombinant protein is the Recombinant Human CD277/BTN3A1 Protein, which has gained significant attention in the scientific community due to its unique structure, diverse activity, and potential applications.
Structure of Recombinant Human CD277/BTN3A1 Protein
The human CD277/BTN3A1 protein is a member of the butyrophilin (BTN) family, which consists of type I transmembrane proteins that are expressed on various immune cells. The recombinant form of CD277/BTN3A1 protein is produced by inserting the DNA sequence encoding the extracellular domain of the protein into a suitable expression system, typically a mammalian cell line.
The recombinant protein contains a signal peptide at its N-terminus, followed by an extracellular domain consisting of two immunoglobulin (Ig)-like domains and a B30.2/SPRY domain. This is followed by a transmembrane domain and a short cytoplasmic tail. The extracellular Ig-like domains are responsible for protein-protein interactions, while the B30.2/SPRY domain is involved in antigen recognition and binding.
Overall, the recombinant CD277/BTN3A1 protein has a similar structure to its native form and retains its functional domains, making it a suitable tool for studying its activity and potential applications.
Activity of Recombinant Human CD277/BTN3A1 Protein
The CD277/BTN3A1 protein is primarily expressed on the surface of T cells, where it acts as a co-stimulatory molecule. It has been shown to interact with other immune cells, such as natural killer (NK) cells, dendritic cells, and B cells, suggesting a role in regulating immune responses.
The recombinant form of CD277/BTN3A1 protein has been extensively studied for its ability to activate Vγ9Vδ2 T cells, a subset of T cells that recognize non-peptide antigens. This activation is dependent on the binding of specific antigens to the B30.2/SPRY domain of CD277/BTN3A1, leading to the activation of downstream signaling pathways and cytokine production.
Moreover, the recombinant protein has also been shown to have anti-tumor activity, as it can activate Vγ9Vδ2 T cells to recognize and kill cancer cells. This makes it a promising candidate for cancer immunotherapy, where it can be used to enhance the body’s natural immune response against tumors.
Applications of Recombinant Human CD277/BTN3A1 Protein
The diverse activity of recombinant CD277/BTN3A1 protein has opened up a wide range of potential applications in the field of immunology and cancer research. One of the major applications is in studying the role of CD277/BTN3A1 in immune responses and its interaction with other immune cells.
Furthermore, the recombinant protein can be used to develop novel cancer immunotherapies, either alone or in combination with other treatments. It can also be used to screen for potential antigens that can activate Vγ9Vδ2 T cells, which could lead to the development of new cancer vaccines.
Additionally, recombinant CD277/BTN3A1 protein can be used in diagnostic assays to detect the presence of specific antigens and monitor immune responses in diseases such as cancer and autoimmune disorders.
Conclusion
The Recombinant Human CD277/BTN3A1 Protein is a valuable tool for studying the structure,
There are no reviews yet.